• Agomab posted a net loss of EUR 31 million for the six months ended June 30, 2026, widening from EUR 26.9 million a year earlier.
• R&D expense edged up to EUR 23 million from EUR 22 million, while G&A costs more than doubled to EUR 12.2 million, due mainly to one-off IPO expenses.
• Cash and cash investments totaled EUR 252 million at June 30, supported by about USD 208 million in gross IPO proceeds; runway is expected into the first half of 2029.
• FDA alignment was reached on key NOV-ERA Phase 2b design elements for ontunisertib in fibrostenosing Crohn’s disease, including a primary endpoint of endoscopic passability at Week 24.
• Topline data from the STENOVA open-label extension for ontunisertib and the Phase 1b IPF cohort for AGMB-447 are expected in coming months, with Phase 2 starts targeted in H2 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agomab Therapeutics NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608061601PRIMZONEFULLFEED1001256440) on August 06, 2026, and is solely responsible for the information contained therein.